[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit ::
Main Menu
Home::
Journal Information::
Articles Archive::
Guide for Authors::
For Reviewers::
Ethical Statements::
Registration::
Site Facilities::
Contact us::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Copyright Policies

 

AWT IMAGE

 

..
Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

..
:: Volume 5 - The Spring Supplement of Shefaye Khatam 2 - ::
Shefaye Khatam 2017, 5 - The Spring Supplement of Shefaye Khatam 2 -: 14-14 Back to browse issues page
O 14: Differentiating Demyelinating Disorders of the Central Nervous System – a Focus on Multiple Sclerosis and Neuromyelitis-Optica Spectrum Disorders
Steffen Pfeuffer *
Institute for Translational Neurology and Neurology Clinic – University Hospital Muenster, Muenster, Germany , steffen.pfeuffer@ukmuenster.de
Abstract:   (3496 Views)

Significant advances have been made in diagnosis and therapy of demyelinating disorders of the central nervous system. The most common entities of this disorders in adults – multiple sclerosis and neuromyelitis optica were initially thought to be different phenotypes of more or less the same disease. During the last ten years, this view was subsequently changed and the term neuromyelitis optica-spectrum disorder (NMOSD) was established. He encompasses a variety of clinical presentations that can mimic MS and other disorders. NMOSD are characterized by certain hallmarks in pathophysiology, especially the presence of different antibodies with high specifity. In clinical routine, a clear differentiation between MS and NMOSD is essential due to significant differences in therapy. Treatment of NMOSD with most substances approved for MS can lead to devastating relapses and even death. Furthermore, the clinical course of NMOSD often is severe and itself leads to massive impairment and high mortality. Neurologists – especially those with a scope on neuroimmunology – need to be familiar with diagnosis and at least acute treatment of this disease. This lecture will give an introduction into epidemiology and pathophysiology of the disorder and will highlight its differences to MS. The new criteria for diagnosis of NMOSD will be presented and discussed including the new category of MOG-spectrum disorders. I also will give insights into current strategies for therapy and review future strategies for therapy.

Keywords: Mortality, Impairment, Neuromyelitis
Full-Text [PDF 206 kb]   (1054 Downloads)    
Type of Study: Review --- Open Access, CC-BY-NC | Subject: Basic research in Neuroscience


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pfeuffer S. O 14: Differentiating Demyelinating Disorders of the Central Nervous System – a Focus on Multiple Sclerosis and Neuromyelitis-Optica Spectrum Disorders. Shefaye Khatam 2017; 5 (S2) :14-14
URL: http://shefayekhatam.ir/article-1-1168-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 5 - The Spring Supplement of Shefaye Khatam 2 - Back to browse issues page
مجله علوم اعصاب شفای خاتم The Neuroscience Journal of Shefaye Khatam
Persian site map - English site map - Created in 0.07 seconds with 45 queries by YEKTAWEB 4645